Eli Lilly and Company announced encouraging results from a Phase 2 trial of lepodisiran, an investigational therapy aimed at reducing levels of lipoprotein(a) [Lp(a)], a genetic risk factor associated with heart disease.

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a mid-stage clinical trial involving 141 patients. Lp(a) is a genetic risk factor for heart attacks,

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease. In clinical trial data published over the weekend, Eli Lilly’s lepodisiran was found to dramatically reduce people’s levels of a dangerous kind of cholesterol called lipoprotein (a), or Lp (a).